Relaying what matters next.

New Glenn’s second launch is slated to send NASA’s twin ESCAPADE orbiters toward Mars on September 29, 2025. Here is why flying interplanetary so early matters for risk, cost, cadence, and competition in the U.S. launch market.

Salesforce just put a sticker price on digital labor. At 10 cents per action, Agentforce 3 pairs unit economics with a reliability stack and a Google partnership that makes agents ready for procurement.

With a fresh DOE loan disbursement on September 16 and summer NRC approvals, Palisades now has a credible path to a Q4 2025 restart. Here is the playbook behind the financing, offtake and licensing, what it means for MISO, and how SMR co-location could multiply the impact.

In 2025, PCSK9 moved from target to strategy. Verve's in vivo base edit delivered dose dependent LDL cuts while oral PCSK9 pills from AstraZeneca and Merck posted pivotal wins, setting up a permanence versus reversibility showdown.

Meta’s Ray-Ban Display smart glasses and Neural Band promise a practical UI for AI agents. With a tiny lens display and subtle wrist gestures, navigation, captions, and on-the-spot guidance shift from chat to action.

A second B-21 Raider has joined the Edwards AFB test team, shifting the program from basic flight trials to mission systems and weapons integration. Here is what that unlocks for sensors, datalinks, EW, LRSO, conventional loadouts, sustainment, and basing.

Saudi Awwal Bank is plugging into Chainlink’s CCIP and CRE to run real onchain finance with audit-ready controls. That unlocks cross-chain DvP, tokenized sukuk servicing, and faster cross-border settlement — and it may let Gulf banks move faster than the United States.

AI data centers are racing into the Permian on islanded gas-plus-battery microgrids while Texas readies 765 kV lines to move bulk ERCOT power west. SB 6 rewrites who pays, how to connect, and when operators must curtail.

On March 19, 2025, ESA's Euclid released Quick Data Release 1, a deep sampler of images, spectra, and catalogs. We unpack what is in Q1, how to access it, early science highlights, and what to watch before DR1 in 2026.

Spring to summer 2025 delivered new U.S. LAP lines and a greenlit Iowa complex, plus fresh European spend. Yet chemistry and small energetics now cap the rate. We map the real chokepoints, why six figures a month slips to mid 2026, and what sustained mass fires mean for doctrine and the Pacific.

The Department of Energy restored LNG approvals in January 2025, clearing a backlog and jump-starting Gulf Coast projects. We break down who advanced, what volumes are realistic for 2026 to 2030, and which bottlenecks like pipelines, labor and methane rules could still slow the surge.

Outcomes data and payer shifts have turned GLP-1s into a population health tool. Here is the biology, the care models, and the metrics that turn pounds into years lived better.

In late August 2025 ESA’s JUICE skimmed past Venus for a high-heat gravity assist while controllers beat a last-minute comms glitch traced to a software timer. Why cameras stayed off, how the team kept the spacecraft cool, and what this flyby sets up next.

Zoom’s AI Companion 3.0 debuts as a low code, cross platform agent that follows you into Teams and Google Meet, automates follow through, and brings enterprise controls. Here is why bring your own agent matters, how it changes Monday workflows, and the questions to ask before you buy.

Australia just locked in a Ghost Shark fleet, signaling that extra‑large autonomous subs are moving from prototypes to massed systems. The shift will reshape anti‑submarine warfare, seabed security, and coalition kill chains across AUKUS.

France and allies just challenged MiCA’s single license promise, hinting at passport vetoes and a push to shift big‑firm oversight to ESMA. We map the legal mechanics, three scenarios, near‑term risks, and how a tightening UK and US corridor could siphon activity.

In 2025, CAISO’s EDAM and SPP’s Markets+ moved from debate to buildout. Here is who joins when, how the seam will work, and what changes by 2026 to 2028.

Three credible trials are dragging senolytics out of mouse lore and into human data. St. Jude pits dasatinib plus quercetin against fisetin, Washington University runs SToMP-AD in early Alzheimer’s, and NIH backs a frailty study in people aging with HIV. Intermittent pulse dosing, functional endpoints like gait speed, and on-target biomarkers could make 2025 the pivot year.